Physician profile
Hanna K Gaggin
NPI 1760597728
$350,203.32
in general payments reported to CMS, 2019-2025
24 companies · $156K in 2025
The $156K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $22K · 2021: $26K · 2022: $26K · 2023: $29K · 2024: $62K · 2025: $156K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $191K · Travel and Lodging: $44K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,850 · Food and Beverage: $2,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $191,253.28 |
| Travel and Lodging | $44,258.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,850.00 |
| Food and Beverage | $2,779.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $80,588.18 | 2019-2025 | Verquvo |
| Novo Nordisk As | $63,057.82 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $51,457.53 | 2024-2025 | |
| Pfizer INC. | $31,008.15 | 2020-2025 | |
| Novo Nordisk INC | $30,953.00 | 2021-2025 | Ozempic |
| Alnylam Pharmaceuticals INC. | $18,884.40 | 2021-2025 | Amvuttra |
| Abbott Laboratories | $16,207.25 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $15,386.06 | 2023-2025 | Wainua |
| Bridgebio Pharma, INC. | $13,592.69 | 2025 | Attruby |
| Amgen INC. | $9,900.00 | 2020-2021 | |
| Roche Diagnostics International Ltd | $8,856.63 | 2019 | |
| Roche Diagnostics Corporation | $5,884.67 | 2019 | |
| Eko Health, INC. | $4,000.00 | 2020 | |
| Radiometer America, INC | $250.00 | 2019 | |
| Edwards Lifesciences Corporation | $91.43 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $49.61 | 2019 | |
| Pfizer Pharmaceuticals Korea Limited | $21.74 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.16 | 2020 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hanna Gaggin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.